Meeting Banner
Abstract #3645

Phospholipid Metabolism Before and During Bevacizumab Therapy in Recurrent Glioma

Ulrich Pilatus1, Oliver Br2, Johannes Rieger2, Stefanie Pellikan1, Maurice Harth1, Joachim Steinbach2, Elke Hattingen1

1Institute of Neuroradiology, Goethe-University Frankfurt, Frankfurt, Germany; 2Dr. Senckenbergisches Institut fr Neuroonkologie, Goethe-University Frankfurt, Frankfurt, Germany

31P and 1H MRSI was used to monitor changes in phospholipid and energy metabolism in recurrent gliomas during antiangiogenic therapy. Elevated PEth/GPE ratios were typical for all recurrent gliomas while high PCho/GPC ratios correlated with the survival time. Both anabolite/katabolite ratios decreased upon onset of therapy. Energy metabolism, mesures as PCr/Pi ratio, was deprived in tumor tissue.

Abstract PDF Presentation Video

Keywords

addition anti appearing assumed brain broken characterized choline compounds concentration concentrations concomitant control correlated cycle days decrease decreased described detectable efficacy elevated energy evaluated every examined exceeding growth hemisphere impaired in vivo includes indicated indicates indicators infiltration initial inorganic institute inversely investigated investigates lipid lipids long longitudinal major malignant marker measured measuring median membrane metabolism metabolites might monitor months negative novel oliver overall patients phenotype phosphate predictive progression quantified recurred recurrent referring refractory related represent represents respective sensitive short significantly spectra spectroscopic start suggests survival terms therapy tissue treatment tumor